Výsledky vyhledávání

Akademický článek

Autor: MONRO, C. BEDELL

Publikováno v: Army Transportation Journal, 1946 Dec 01. 2(11), 18-20.

Externí odkaz: https://www.jstor.org/stable/44094520

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

Autor: D Shawler, Neil Senzer, P Snitz, P B Maples, Michael Nemunaitis, B O Pappen, P Kumar, John Nemunaitis, C. Bedell, H Fakhrai

Publikováno v: Cancer gene therapy. 16(8)

In a previous dose escalation trial we demonstrated dose related survival correlation to Belagenpumatucel-L. In order to further evaluate safety and response at the previously defined optimal dose and schedule and to gain preliminary evidence on a hy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d41745acc3822d9427241ec764cf006
https://pubmed.ncbi.nlm.nih.gov/19287371

Zobrazit plný text záznamu

Correlation between myocardial malate/aspartate shuttle activity and EAAT1 protein expression in hyper- and hypothyroidism

Autor: Thomas D. Scholz, Kurt C. Bedell, Jeffrey L. Segar, J. Carter Ralphe

Publikováno v: American journal of physiology. Heart and circulatory physiology. 288(5)

In the heart, elevated thyroid hormone leads to upregulation of metabolic pathways associated with energy production and development of hypertrophy. The malate/aspartate shuttle, which transfers cytosolic-reducing equivalents into the cardiac mitocho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::972975146bff965e37acc6ec255293eb
https://pubmed.ncbi.nlm.nih.gov/15615843

Zobrazit plný text záznamu

Systemic Benefit of Gm-Csf-Encoding, Oncolytic Herpes Virus (Talimogene Laherparepvec, T-Vec) in Metastatic Melanoma: Phase Ii Assessment

Autor: C. Bedell, S. Horvath, Neil Senzer, John Nemunaitis

Publikováno v: Annals of Oncology. 25:iv365

Aim: We and others previously conducted a multicenter phase II trial to assess the efficacy and safety of T-VEC, an oncolytic immunotherapy derived from herpes simplex virus type-1, in advanced stage IIIC and IV melanoma patients (Senzer, Nemunaitis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d94106c66f22927956eeb7f53f0d1d5
https://doi.org/10.1093/annonc/mdu342.12

Zobrazit plný text záznamu

Hemodynamic responses to cold stress in blacks: effect of application site

Autor: W J, Duey, H N, Williford, D R, Bassett, M, Sharff-Olson, C, Bedell, G, Lloyd, E, Rogers

Publikováno v: Ethnicitydisease. 6(3-4)

Black Americans have been shown to exhibit increased blood pressure responses to a variety of physical stressors. However, few investigators have examined hemodynamic responses to cold stress. Additionally, no studies have compared blood pressure res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::59ae253eabebe33292267af40526afb5
https://pubmed.ncbi.nlm.nih.gov/9086317

Zobrazit plný text záznamu

A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies

Autor: Christian Scheffold, Gerald Edelman, Linh Nguyen, A. D. Laird, Shuchi Sumant Pandya, Jordi Rodon, E. L. Kwak, Geoffrey I. Shapiro, J. Baselga, C. Bedell

Publikováno v: Journal of Clinical Oncology. 28:3004-3004

3004 Background: XL147 is a selective inhibitor of class I PI3K isoforms. In preclinical cancer models, XL147 is cytostatic or cytoreductive as monotherapy and enhances the efficacy of targeted agents and chemotherapeutics. This open label, phase I d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::df3b77b531720832e0dca07cb4fda1b4
https://doi.org/10.1200/jco.2010.28.15_suppl.3004

Zobrazit plný text záznamu

Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer

Autor: C. Bedell, L. T. Campos, Svetislava J. Vukelja, Donald A. Richards, J. P. Letzer, William J. Hyman, Peter Sportelli, L. Gardner, John Nemunaitis, Christopher Hagenstad

Publikováno v: Journal of Clinical Oncology. 27:4081-4081

4081 Background: Perifosine (Peri), a synthetic alkylphospholipid, inhibits or modifies a number of different signal transduction pathways (AKT, MAPK and JNK). Peri as a single agent or in combination with other cytotoxic agents, has shown clinical b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e6bb55f0a4708f86ea41e01d9f54daeb
https://doi.org/10.1200/jco.2009.27.15_suppl.4081

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání